Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


The number of overweight and obese adults and children has markedly increased over the past several decades. Compared to healthy weight people the obese population is at a greater risk of a number of chronic conditions including diabetes and cardiovascular disease. Recent research has shown a strong link in obese women between being overweight and the occurrence of postmenopausal breast cancer.

Read more

The way we treat cancer is rapidly evolving. Over the years we have learnt that grouping together patients based on their cancer type and then treating them all with the same agent has limited success and leads to incredibly high attrition rates. Researchers are now undertaking a radically different approach in umbrella trials, including the innovative Matrix NSCLC study, dividing patients within a cancer type by the genetic makeup of their tumor and testing multiple treatments in parallel.

Read more

After losing the immunotherapy melanoma approval race to Merck’s Keytruda®, Bristol-Meyers Squibb has got its hands on a much bigger piece of the pie by getting its own drug, Opdivo® accepted more than three months ahead of schedule for the treatment of squamous NSCLC.

Read more

After being considered as the next big thing in cancer drug development in the 1990s, PARP inhibitors were given up for dead in 2011. These compounds are now being revived as Lynparza™ (olaparib) was approved in late 2014 for the treatment of advanced ovarian cancer. A recent study published in Nature Reviews Cancer highlights potential therapeutic targets in DNA Damage Response (DDR) pathways, which need careful translational planning to avoid the long route to market that PARP Inhibitors took.

Read more

Diabetes treatment is based around the tight management of blood sugar levels via healthy eating, physical activity, regular monitoring, and medication or insulin if required. While this is effective in younger patients, a new study has found that a ‘one size fits all approach’ to diabetes control could lead to over treatment and potential harm in older patients.

Read more